Switch to:
Also traded in: Germany, Mexico, Spain, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
GRFS's Cash-to-Debt is ranked higher than
87% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. GRFS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GRFS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.25 Max: No Debt
Current: No Debt
Equity-to-Asset 0.37
GRFS's Equity-to-Asset is ranked lower than
78% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. GRFS: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
GRFS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.07  Med: 0.34 Max: 0.4
Current: 0.37
0.07
0.4
Interest Coverage 3.90
GRFS's Interest Coverage is ranked lower than
92% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GRFS: 3.90 )
Ranked among companies with meaningful Interest Coverage only.
GRFS' s Interest Coverage Range Over the Past 10 Years
Min: 1.56  Med: 4.15 Max: 18.28
Current: 3.9
1.56
18.28
Piotroski F-Score: 5
Altman Z-Score: 2.41
Beneish M-Score: -2.07
WACC vs ROIC
5.65%
13.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 23.20
GRFS's Operating Margin % is ranked higher than
88% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. GRFS: 23.20 )
Ranked among companies with meaningful Operating Margin % only.
GRFS' s Operating Margin % Range Over the Past 10 Years
Min: 14.04  Med: 23.93 Max: 26.85
Current: 23.2
14.04
26.85
Net Margin % 13.47
GRFS's Net Margin % is ranked higher than
85% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. GRFS: 13.47 )
Ranked among companies with meaningful Net Margin % only.
GRFS' s Net Margin % Range Over the Past 10 Years
Min: 2.8  Med: 12.13 Max: 16.2
Current: 13.47
2.8
16.2
ROE % 15.81
GRFS's ROE % is ranked higher than
90% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. GRFS: 15.81 )
Ranked among companies with meaningful ROE % only.
GRFS' s ROE % Range Over the Past 10 Years
Min: 4.27  Med: 18.11 Max: 45.78
Current: 15.81
4.27
45.78
ROA % 5.67
GRFS's ROA % is ranked higher than
86% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. GRFS: 5.67 )
Ranked among companies with meaningful ROA % only.
GRFS' s ROA % Range Over the Past 10 Years
Min: 1.34  Med: 5.72 Max: 11.51
Current: 5.67
1.34
11.51
ROC (Joel Greenblatt) % 32.59
GRFS's ROC (Joel Greenblatt) % is ranked higher than
88% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. GRFS: 32.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GRFS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 10.9  Med: 31.94 Max: 41.3
Current: 32.59
10.9
41.3
3-Year Revenue Growth Rate 13.70
GRFS's 3-Year Revenue Growth Rate is ranked higher than
65% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. GRFS: 13.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GRFS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 13.7  Med: 18.9 Max: 28.2
Current: 13.7
13.7
28.2
3-Year EBITDA Growth Rate 10.40
GRFS's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. GRFS: 10.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GRFS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 10.4  Med: 34.1 Max: 38.4
Current: 10.4
10.4
38.4
3-Year EPS without NRI Growth Rate 16.20
GRFS's 3-Year EPS without NRI Growth Rate is ranked higher than
70% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. GRFS: 16.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GRFS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -9.2  Med: 27.7 Max: 105.1
Current: 16.2
-9.2
105.1
GuruFocus has detected 2 Warning Signs with Grifols SA $GRFS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GRFS's 10-Y Financials

Financials (Next Earnings Date: 2017-05-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

GRFS Guru Trades in Q1 2016

Jim Simons 188,304 sh (New)
Ron Baron 75,000 sh (+7.14%)
Mario Gabelli 57,400 sh (unchged)
John Paulson 17,533,764 sh (-29.29%)
» More
Q2 2016

GRFS Guru Trades in Q2 2016

Ron Baron 75,000 sh (unchged)
Jim Simons Sold Out
Mario Gabelli 55,800 sh (-2.79%)
John Paulson 7,345,166 sh (-58.11%)
» More
Q3 2016

GRFS Guru Trades in Q3 2016

Jim Simons 28,804 sh (New)
Ron Baron 75,000 sh (unchged)
Mario Gabelli 40,625 sh (-27.20%)
John Paulson 2,478,600 sh (-66.26%)
» More
Q4 2016

GRFS Guru Trades in Q4 2016

John Paulson Sold Out
Jim Simons Sold Out
Mario Gabelli 30,000 sh (-26.15%)
Ron Baron 40,000 sh (-46.67%)
» More
» Details

Insider Trades

Latest Guru Trades with GRFS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412 
Compare:OTCPK:NVZMY, OTCPK:GMXAY, OTCPK:UCBJF, NAS:SGEN, NAS:ALKS, NAS:BMRN, NAS:JAZZ, NAS:TSRO, NAS:EXEL, NAS:UTHR, NAS:BIVV, NAS:IONS, NAS:ALNY, NAS:KITE, NAS:ARIA, NAS:ACAD, NAS:TECH, NAS:GLPG, NAS:BLUE, NAS:RARE » details
Traded in other countries:G0FB.Germany, GRFPN.Mexico, GRF.P.Spain, 0RDU.UK, GIKLY.USA,
Grifols SA is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. It operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials and Others.

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 90% of sales in 2013. Grifols also has smaller segments including diagnostics, hospital supplies, and raw materials, but diagnostics grew to almost 20% of revenue in 2014 with the acquisition of Novartis' diagnostics unit.

Ratios

vs
industry
vs
history
PE Ratio 26.94
GRFS's PE Ratio is ranked higher than
52% of the 272 Companies
in the Global Biotechnology industry.

( Industry Median: 27.67 vs. GRFS: 26.94 )
Ranked among companies with meaningful PE Ratio only.
GRFS' s PE Ratio Range Over the Past 10 Years
Min: 21.8  Med: 33.38 Max: 96.2
Current: 26.94
21.8
96.2
Forward PE Ratio 15.95
GRFS's Forward PE Ratio is ranked lower than
53% of the 78 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. GRFS: 15.95 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 26.94
GRFS's PE Ratio without NRI is ranked higher than
52% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. GRFS: 26.94 )
Ranked among companies with meaningful PE Ratio without NRI only.
GRFS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 21.72  Med: 32.26 Max: 97.1
Current: 26.94
21.72
97.1
Price-to-Owner-Earnings 45.11
GRFS's Price-to-Owner-Earnings is ranked lower than
66% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 26.25 vs. GRFS: 45.11 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GRFS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.07  Med: 33.11 Max: 47.23
Current: 45.11
18.07
47.23
PB Ratio 4.01
GRFS's PB Ratio is ranked lower than
52% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. GRFS: 4.01 )
Ranked among companies with meaningful PB Ratio only.
GRFS' s PB Ratio Range Over the Past 10 Years
Min: 2.32  Med: 4.18 Max: 6.76
Current: 4.01
2.32
6.76
PS Ratio 3.69
GRFS's PS Ratio is ranked higher than
78% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. GRFS: 3.69 )
Ranked among companies with meaningful PS Ratio only.
GRFS' s PS Ratio Range Over the Past 10 Years
Min: 1.9  Med: 3.5 Max: 6.38
Current: 3.69
1.9
6.38
Price-to-Free-Cash-Flow 56.90
GRFS's Price-to-Free-Cash-Flow is ranked lower than
76% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 22.69 vs. GRFS: 56.90 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GRFS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 15.58  Med: 30.29 Max: 117.79
Current: 56.9
15.58
117.79
Price-to-Operating-Cash-Flow 26.87
GRFS's Price-to-Operating-Cash-Flow is ranked lower than
60% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 23.59 vs. GRFS: 26.87 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GRFS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.01  Med: 18.74 Max: 169.33
Current: 26.87
11.01
169.33
EV-to-EBIT 14.99
GRFS's EV-to-EBIT is ranked higher than
56% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. GRFS: 14.99 )
Ranked among companies with meaningful EV-to-EBIT only.
GRFS' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.9  Med: 19.8 Max: 44.5
Current: 14.99
11.9
44.5
EV-to-EBITDA 12.30
GRFS's EV-to-EBITDA is ranked higher than
56% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. GRFS: 12.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
GRFS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.8  Med: 16 Max: 34.5
Current: 12.3
9.8
34.5
PEG Ratio 1.28
GRFS's PEG Ratio is ranked higher than
64% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. GRFS: 1.28 )
Ranked among companies with meaningful PEG Ratio only.
GRFS' s PEG Ratio Range Over the Past 10 Years
Min: 0.6  Med: 1.12 Max: 1.77
Current: 1.28
0.6
1.77
Current Ratio 2.91
GRFS's Current Ratio is ranked lower than
63% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. GRFS: 2.91 )
Ranked among companies with meaningful Current Ratio only.
GRFS' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 2.92 Max: 3.36
Current: 2.91
1.67
3.36
Quick Ratio 1.38
GRFS's Quick Ratio is ranked lower than
78% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. GRFS: 1.38 )
Ranked among companies with meaningful Quick Ratio only.
GRFS' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.52 Max: 1.74
Current: 1.38
0.74
1.74
Days Inventory 259.41
GRFS's Days Inventory is ranked lower than
80% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. GRFS: 259.41 )
Ranked among companies with meaningful Days Inventory only.
GRFS' s Days Inventory Range Over the Past 10 Years
Min: 235.92  Med: 290.24 Max: 763.71
Current: 259.41
235.92
763.71
Days Sales Outstanding 37.27
GRFS's Days Sales Outstanding is ranked higher than
70% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. GRFS: 37.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
GRFS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 33.61  Med: 68.57 Max: 97.36
Current: 37.27
33.61
97.36
Days Payable 78.73
GRFS's Days Payable is ranked higher than
59% of the 341 Companies
in the Global Biotechnology industry.

( Industry Median: 59.13 vs. GRFS: 78.73 )
Ranked among companies with meaningful Days Payable only.
GRFS' s Days Payable Range Over the Past 10 Years
Min: 64.56  Med: 101.37 Max: 256.52
Current: 78.73
64.56
256.52

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.00
GRFS's Dividend Yield % is ranked higher than
69% of the 223 Companies
in the Global Biotechnology industry.

( Industry Median: 1.29 vs. GRFS: 2.00 )
Ranked among companies with meaningful Dividend Yield % only.
GRFS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.38  Med: 1.23 Max: 2.07
Current: 2
0.38
2.07
Dividend Payout Ratio 0.41
GRFS's Dividend Payout Ratio is ranked higher than
81% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. GRFS: 0.41 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GRFS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.2  Med: 0.34 Max: 0.56
Current: 0.41
0.2
0.56
3-Year Dividend Growth Rate 46.30
GRFS's 3-Year Dividend Growth Rate is ranked higher than
93% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 8.70 vs. GRFS: 46.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
GRFS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 46.3
Current: 46.3
0
46.3
Forward Dividend Yield % 2.18
GRFS's Forward Dividend Yield % is ranked higher than
76% of the 208 Companies
in the Global Biotechnology industry.

( Industry Median: 1.22 vs. GRFS: 2.18 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.00
GRFS's 5-Year Yield-on-Cost % is ranked higher than
64% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. GRFS: 2.00 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GRFS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.38  Med: 1.23 Max: 2.07
Current: 2
0.38
2.07
3-Year Average Share Buyback Ratio 0.20
GRFS's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. GRFS: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GRFS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -46.1  Med: -1.5 Max: 0.2
Current: 0.2
-46.1
0.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.92
GRFS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
66% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.22 vs. GRFS: 1.92 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GRFS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.65  Med: 2.2 Max: 2.75
Current: 1.92
1.65
2.75
Price-to-Median-PS-Value 1.05
GRFS's Price-to-Median-PS-Value is ranked lower than
52% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. GRFS: 1.05 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GRFS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.58  Med: 0.98 Max: 1.55
Current: 1.05
0.58
1.55
Price-to-Peter-Lynch-Fair-Value 1.33
GRFS's Price-to-Peter-Lynch-Fair-Value is ranked higher than
62% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.48 vs. GRFS: 1.33 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
GRFS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.11  Med: 1.13 Max: 1.33
Current: 1.33
1.11
1.33
Earnings Yield (Greenblatt) % 6.69
GRFS's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. GRFS: 6.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GRFS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.2  Med: 5.1 Max: 8.4
Current: 6.69
2.2
8.4
Forward Rate of Return (Yacktman) % 22.92
GRFS's Forward Rate of Return (Yacktman) % is ranked higher than
60% of the 124 Companies
in the Global Biotechnology industry.

( Industry Median: 15.21 vs. GRFS: 22.92 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GRFS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 18.4  Med: 24.7 Max: 42
Current: 22.92
18.4
42

More Statistics

Revenue (TTM) (Mil) $4,464
EPS (TTM) $ 0.89
Beta1.32
Short Percentage of Float0.23%
52-Week Range $14.27 - 18.00
Shares Outstanding (Mil)682.82

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 4,459 4,677
EPS ($) 1.09 1.19
EPS without NRI ($) 1.09 1.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.85%
Dividends per Share ($) 0.41 0.44
» More Articles for GRFS

Headlines

Articles On GuruFocus.com
John Paulson's Largest 3rd Quarter Trades Dec 01 2016 
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Mar 18 2016 
Gold-Focused Guru John Paulson Reports First Quarter Holdings May 22 2014 
Is Grifols Being Overlooked? Mar 19 2014 
John Paulson's Top Five Holdings Nov 20 2013 
John Paulson's Top Five Holdings Sep 12 2013 
Baron Funds Comments on Grifols SA Aug 30 2012 
Friday Value Overview Aug 19 2011 

More From Other Websites
5 Cheap PEG Picks for Value Investors Right Now Mar 22 2017
Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod Mar 21 2017
AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal Mar 20 2017
Is Grifols a Great Stock for Value Investors? Mar 17 2017
New Strong Buy Stocks for March 9th Mar 09 2017
Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 8.6% Mar 09 2017
5 European Stocks to Buy as Trump Rally Weakens Mar 07 2017
Grifols SA :GRFS-US: Earnings Analysis: 2016 By the Numbers : March 6, 2017 Mar 06 2017
Grifols SA :GRFS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017 Mar 03 2017
Blog Coverage Kite Pharma CAR-T Cancer Therapy Demonstrate Positive Results in B-cell non-Hodgkin... Mar 02 2017
Grifols closes the acquisition of Hologic's share of NAT donor screening unit for USD 1,850 million Jan 31 2017
Hologic Completes Divestiture of Blood Screening Business Jan 31 2017
Grifols SA : GRFS-US: Dividend Analysis : December 07th, 2016 (record date) : By the numbers :... Jan 30 2017
Grifols, S.A. upgraded by JP Morgan Jan 03 2017
Hologic (HOLX) to Divest Blood Screening Business to Grifols Dec 19 2016
Hologic Still A Buy After Getting 'Lofty' Price For Blood-Screening Unit Dec 15 2016
Hologic Agrees to Sell Blood Screening Business to Grifols for $1.85B Dec 14 2016
Grifols to buy Hologic's stake in blood screening JV for $1.85 billion Dec 14 2016
Grifols agrees to acquire Hologic's share of NAT donor screening unit for USD 1,850 million Dec 14 2016
Hologic to Divest Blood Screening Business to Partner Grifols for $1.85 Billion Dec 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)